GLIOPEP, a three-year international research consortium supported by the Eurostars-3 programme and co-funded by Vinnova.
Bringing together Oncopeptides, Uppsala University, Xenopat (Spain), and Crown Bioscience (Netherlands), the project evaluated novel peptide-drug conjugates (PDCs) against glioblastoma—one of the most aggressive forms of brain cancer. Over three years, the partners developed clinically relevant in vitro, ex vivo, and in vivo models.
The consortium met all planned objectives, with results exceeding expectations across several study systems. These findings provide compelling preclinical evidence that reinforces Oncopeptides’ strategic decision to prioritize glioblastoma as a core pipeline program moving toward clinical development.
As previously communicated, Oncopeptides has received approximately SEK 3.3 million in funding through Eurostars-3/Vinnova, matched by an equivalent co-funding commitment from the company.
About GLIOPEP
- Duration: 3 years
- Programme: Eurostars-3 (Co-funded by the EU and Vinnova)
- Consortium: Oncopeptides AB (Sweden), Uppsala University (Sweden), Xenopat S.L. (Spain), Crown Bioscience (Netherlands)
- Focus: Preclinical evaluation of peptide-drug conjugates for glioblastoma
- Outcome: All objectives achieved; results exceed expectations and support progression toward clinical studies
